| Carolyn Dale Denton, DO | |
|
508 N Riedel St, Yorktown, TX 78164-1810 | |
| (361) 564-9230 | |
| (361) 564-9246 |
| Full Name | Carolyn Dale Denton |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 508 N Riedel St, Yorktown, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447344635 | NPI | - | NPPES |
| 1F5097 | Other | TX | MEDICARE |
| 155386908 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L5302 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cuero Community Hospital Home Health Agency | Cuero, TX | Home health agency |
| Cuero Regional Hospital | Cuero, TX | Hospital |
| De Tar Hospital Navarro | Victoria, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dewitt Medical District | 3072421395 | 19 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
Women with HIV infection who become pregnant have a lower risk of progression to AIDS and death, researchers at Vanderbilt University Medical Center report.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
Digital security is a key requirement in our product designs, especially in markets such as healthcare where the design is complete long before final regulatory approval. From a commercial point of view, ignoring data privacy, device authentication, and anti-counterfeit at design stage is no longer a tenable position for a connected product that produces sensitive patient data – even if it is nominally pseudonomised.
› Verified 2 days ago
| Entity Name | Dewitt Medical District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366532608 PECOS PAC ID: 3072421395 Enrollment ID: O20031202000088 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
Women with HIV infection who become pregnant have a lower risk of progression to AIDS and death, researchers at Vanderbilt University Medical Center report.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
Digital security is a key requirement in our product designs, especially in markets such as healthcare where the design is complete long before final regulatory approval. From a commercial point of view, ignoring data privacy, device authentication, and anti-counterfeit at design stage is no longer a tenable position for a connected product that produces sensitive patient data – even if it is nominally pseudonomised.
› Verified 2 days ago
| Entity Name | Ucp Physicians Of Central Texas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922289412 PECOS PAC ID: 3173697935 Enrollment ID: O20080729000203 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
Women with HIV infection who become pregnant have a lower risk of progression to AIDS and death, researchers at Vanderbilt University Medical Center report.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
Digital security is a key requirement in our product designs, especially in markets such as healthcare where the design is complete long before final regulatory approval. From a commercial point of view, ignoring data privacy, device authentication, and anti-counterfeit at design stage is no longer a tenable position for a connected product that produces sensitive patient data – even if it is nominally pseudonomised.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carolyn Dale Denton, DO 508 N Riedel St, Yorktown, TX 78164-1810 Ph: (361) 564-9230 | Carolyn Dale Denton, DO 508 N Riedel St, Yorktown, TX 78164-1810 Ph: (361) 564-9230 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
Women with HIV infection who become pregnant have a lower risk of progression to AIDS and death, researchers at Vanderbilt University Medical Center report.
A single dose of radiotherapy is as "effective" as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.
Digital security is a key requirement in our product designs, especially in markets such as healthcare where the design is complete long before final regulatory approval. From a commercial point of view, ignoring data privacy, device authentication, and anti-counterfeit at design stage is no longer a tenable position for a connected product that produces sensitive patient data – even if it is nominally pseudonomised.
› Verified 2 days ago
Dr. Gordon Barth, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 508 N Riedel St, Yorktown, TX 78164 Phone: 361-564-3383 Fax: 361-564-4224 |